Abstract
The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pyloridis. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 microgram/ml; rifampin was less active, with MICs ranging from 0.25 to greater than 1 microgram/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barlam T., Neu H. C. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Apr;25(4):529–531. doi: 10.1128/aac.25.4.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Flores B. M., Fennell C. L., Holmes K. K., Stamm W. E. In vitro susceptibilities of Campylobacter-like organisms to twenty antimicrobial agents. Antimicrob Agents Chemother. 1985 Aug;28(2):188–191. doi: 10.1128/aac.28.2.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fricker C. R., Park R. W. Urease-positive camplyobacters. Lancet. 1985 Feb 16;1(8425):394–394. doi: 10.1016/s0140-6736(85)91411-4. [DOI] [PubMed] [Google Scholar]
- Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones D. M., Lessells A. M., Eldridge J. Campylobacter like organisms on the gastric mucosa: culture, histological, and serological studies. J Clin Pathol. 1984 Sep;37(9):1002–1006. doi: 10.1136/jcp.37.9.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kasper G., Dickgiesser N. Antibiotic sensitivity of "Campylobacter pylori". Eur J Clin Microbiol. 1984 Oct;3(5):444–444. doi: 10.1007/BF02017370. [DOI] [PubMed] [Google Scholar]
- Marshall B. J., Warren J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984 Jun 16;1(8390):1311–1315. doi: 10.1016/s0140-6736(84)91816-6. [DOI] [PubMed] [Google Scholar]
- McNulty C. A., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985 Dec;28(6):837–838. doi: 10.1128/aac.28.6.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McNulty C. A., Watson D. M. Spiral bacteria of the gastric antrum. Lancet. 1984 May 12;1(8385):1068–1069. doi: 10.1016/s0140-6736(84)91469-7. [DOI] [PubMed] [Google Scholar]
- Megraud F., Bonnet F., Garnier M., Lamouliatte H. Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content. J Clin Microbiol. 1985 Dec;22(6):1007–1010. doi: 10.1128/jcm.22.6.1007-1010.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Price A. B., Levi J., Dolby J. M., Dunscombe P. L., Smith A., Clark J., Stephenson M. L. Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut. 1985 Nov;26(11):1183–1188. doi: 10.1136/gut.26.11.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rollason T. P., Stone J., Rhodes J. M. Spiral organisms in endoscopic biopsies of the human stomach. J Clin Pathol. 1984 Jan;37(1):23–26. doi: 10.1136/jcp.37.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 Jun 4;1(8336):1273–1275. [PubMed] [Google Scholar]